MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-07-2024
Avinger Net Income 2011-2025 | AVGR
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Avinger
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.3 M | -17.6 M | -17.4 M | -19 M | -19.4 M | -27.6 M | -48.7 M | -56.1 M | -47.3 M | -32 M | -39.9 M | -33.9 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -17.4 M | -56.1 M | -31.4 M |
Quarterly Net Income Avinger
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.71 M | -4.36 M | -5.52 M | - | -4.48 M | -4.18 M | -4.64 M | - | -4.09 M | -4.21 M | -5.14 M | - | -4.91 M | -2.45 M | -5.05 M | - | -4.52 M | -4 M | -5.85 M | - | -4.62 M | -4.65 M | -5.06 M | - | -5.39 M | -5.8 M | -10.3 M | - | -10.4 M | -12.8 M | -15.3 M | -13.5 M | -13 M | -13.5 M | -16.2 M | -13.5 M | -13.2 M | -10.2 M | -12.8 M | -8.14 M | -8.78 M | -7.08 M | -7.97 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.45 M | -16.2 M | -7.76 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apyx Medical Corporation
APYX
|
-18.7 M | $ 3.86 | -3.26 % | $ 134 M |  USA |
 |
BioSig Technologies
BSGM
|
-10.3 M | - | 37.08 % | $ 85.7 M | USA |
 |
Abiomed
ABMD
|
226 M | - | - | $ 17.2 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
-716 M | $ 307.92 | -1.93 % | $ 8.69 B | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Bruker Corporation
BRKR
|
113 M | $ 45.13 | -2.67 % | $ 6.72 K | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
Abbott Laboratories
ABT
|
13.4 B | $ 125.1 | 1.48 % | $ 218 B | USA |
 |
Boston Scientific Corporation
BSX
|
1.85 B | $ 92.34 | 0.64 % | $ 136 B | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | $ 2.56 | 8.94 % | $ 95.5 M |  France |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
-9.57 M | $ 0.92 | -4.72 % | $ 14.8 M | USA |
 |
IRadimed Corporation
IRMD
|
19.2 M | $ 96.35 | -1.06 % | $ 1.22 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-37.8 M | $ 17.7 | -3.46 % | $ 408 M | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
63.2 M | $ 62.79 | -1.82 % | $ 3.41 B |  Britain |
 |
Pulmonx Corporation
LUNG
|
-56.4 M | $ 2.53 | 0.86 % | $ 99 M | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
InMode Ltd.
INMD
|
181 M | $ 14.56 | 0.76 % | $ 1.15 B | Israel |
 |
Cognyte Software Ltd.
CGNT
|
-12.1 M | $ 9.88 | 0.05 % | $ 709 M | Israel |
 |
Myomo
MYO
|
-10.7 M | $ 1.06 | -1.85 % | $ 7.47 M | USA |
 |
Second Sight Medical Products
EYES
|
-23.5 M | - | -0.97 % | $ 54.4 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
-6.94 M | $ 13.41 | -4.56 % | $ 1.03 B | USA |
 |
NuVasive
NUVA
|
40.4 M | - | - | $ 2.07 B | USA |
 |
Align Technology
ALGN
|
421 M | $ 165.15 | 0.78 % | $ 12.4 B | USA |
 |
Accuray Incorporated
ARAY
|
-1.59 M | $ 1.07 | -3.18 % | $ 110 M | USA |
 |
ClearPoint Neuro
CLPT
|
-18.9 M | $ 12.81 | -1.23 % | $ 346 M | USA |
 |
Orthofix Medical
OFIX
|
-126 M | $ 15.51 | -1.27 % | $ 591 M |  Curacao |
 |
FONAR Corporation
FONR
|
12.4 M | $ 14.86 | -0.03 % | $ 97.4 M | USA |
 |
AxoGen
AXGN
|
-9.96 M | $ 30.33 | 1.15 % | $ 1.34 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
132 M | $ 40.78 | 2.33 % | $ 1.26 B | USA |
|
LENSAR
LNSR
|
-31.4 M | $ 11.48 | -0.17 % | $ 132 M | USA |